academia has you beefing with someone 3k miles away who is also one of only 4 people on earth who likes the same stuff as you

It’s always bothered me that the WHO says health is “not merely the absence of disease” like that’s such an easy thing to achieve.

A common theory behind increased RSV cases numbers among children after the end of Covid lockdowns was “immunity debt”. In this fascinating analysis now in Clinical Infectious Diseases, another explanation emerges--vastly increased testing, esp of older kids. sabeti_lab doi.org/10.1093/cid/ci…

In our first year we’ve received more than 3.4K Altmetric mentions 👏 This month we’re celebrating one year of BMJ Oncology 🥳 Discover our most popular content: bit.ly/48GReNH

Check out new study in AJMC led by Aaron Schwartz and myself, looking at #COVID19 impacts on 5 metrics of low-value #cancer care. What happened? Not that much! Interesting implications for value-based care programs when a global #pandemic doesn't curb low-value care.... #vbc

What happened to low-value cancer care when the COVID-19 pandemic massively disrupted health care delivery? Ravi B. Parikh led this new study in AJMC. We were a bit surprised by the results. ajmc.com/view/trends-in…

I fear that even the complimentary cupcakes and water bottles during Laboratory Professionals Week may not be enough to eradicate burnout.

jcp.bmj.com/content/77/2/9…

If you liked not seeing the sun today consider a career in pathology

Shifting tides: the rising tide of early-onset cancers demands attention. This article got lots of attention in our first year of publishing 👇 #Oncology #BMJOncology

JHU Path is recruiting for our 2026-2027 surgical pathology fellowship, which offers trainees the opportunity to independently sign out cases in a highly supported setting. Applications may be submitted now and acceptances are on a rolling basis until the program is filled.

I can’t believe EPIC-SR was literally published after the pandemic ended. nejm.org/doi/full/10.10…

Perspective by Benjamin Vipler, MD, MEd: “What’s Lymphoma?” — Risks Posed by Immediate Release of Test Results to Patients nej.md/3wXaKbK

#ClinicalMedicine

In this study of phase 3 oncology trials, nearly half of trials presented a subgroup analysis in their primary publication. However, most claims did not appear to be highly or moderately credible.

Ethan Ludmir MD Alexander Sherry JAMA Network Open

jamanetwork.com/journals/jaman…

What is everyone doing to celebrate me on this holiest of National Doctors Day?

I need to apologize. In my latest video, I said clinical pathologist when I should have said anatomic pathologist. I feel an incredible amount of shame over this. The pathology community has shunned me. My family won’t talk to me. Please forgive me.

A recent review in The Lancet Oncology highlights examples of drugs, authorised on the basis of surrogate endpoints, that were later withdrawn due to an absence of overall survival benefit. It calls for regulators to insist on robust evidence.

thelancet.com/journals/lanon…

I hate when pathology crashes my differential diagnosis party.

Teaching Josh Gottlieb (also @GottliebEcon.you.know.where) et al. QJE again today gottlieb.ca/papers/Doctors…

Such a rich/dense piece of scholarship on physician earnings.

This subfigure drew my attention today. Docs earn more at smaller practices.

I wrote about Daniel Kahneman, who really loved to be wrong.

theatlantic.com/science/archiv…

I proposed a cancer overdiagnosis awareness month in 2016.

bostonglobe.com/ideas/2016/12/…